12
Jun

Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences’ dominance in the field.

…read more

Source: J&J teams with Glaxo’s ViiV on an HIV combo treatment

    

0 No comments